Humana price target raised to $300 from $270 at Baird

Baird raised the firm’s price target on Humana (HUM) to $300 from $270 and keeps a Neutral rating on the shares. The firm sees minimal incremental buyers of stocks in the managed care and healthcare facilities group until the policy overhang clears. Baird does not not expect guidance raises as it believes companies will maintain 2025 “conservatism and cushion” given potential Part D and macro headwinds that may evolve later this year.